AnBogen Therapeutics Secures $7.3 Million in Series A Funding to Advance Precision Oncology Pipeline

AnBogen Therapeutics, a precision oncology company based in Taiwan, has successfully raised $7.3 million in funding. The company is focused on developing personalized therapeutics to address the unmet needs in cancer treatment. AnBogen Therapeutics is driven by a mission to make a difference in patients' lives by bridging the gap between discovery candidates and proof-of-concept indications. With a pipeline of precision medicines targeting solid tumors, the company is advancing assets like ABT-101 and ABT-301 through clinical development. This recent funding will support the continued research and development efforts of AnBogen Therapeutics as they strive to bring first/best-in-class therapies to patients in need.